



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0


F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

HN801c : Head and neck squamous cell carcinoma tissue array, including pathology grade, TNM and clinical stage (AJCC 8th edition), 40 cases/80 cores, replacing HN801b

Microarray Panel	Head and neck squamous cell carcinoma tissue microarray, containing 30 cases of squamous cell carcinoma, 7 normal tissue and 3 adjacent tissue, duplicate cores per case		
Cores	80	HN801c H&E 	
Cases	40		
Row number	8		
Column number	10		
Core Diameter (mm)	1.5		
Thickness (µm)	5		
Tissue Array Type	FFPE		
Species	Human		
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.		
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, "*" means invalid core; "-" means no applicable or negative in IHC markers.		

	1	2	3	4	5	6	7	8	9	10
A	Lar	Lar	Lar	Lar	Gin	Gin	Che	Che	Lar	Lar
B	Ton	Ton	Ton	Ton	Lip	Lip	Ton	Ton	Lar	Lar
C	Lar	Lar	Lar	Lar	Che	Che	Lar	Lar	Voc	Voc
D	Lar	Lar	Lar	Lar	Lar	Lar	Lar	Lar	Nos	Nos
E	Lar	Lar	Max	Max	Lip	Lar	Lar	Lar	Lar	Lar
F	Lar	Lar	Lar	Lar	Lar	Lar	Nos	Nos	Lar	Lar
G	Epi	Epi	Lar	Lar	Lar	Lar	Ton	Ton	Ton	Ton
H	Ton	Ton	Ton	Ton	Ton	Ton	Ton	Ton	Nos	Nos

Legend: Che - Cheek, Epi - Epiglottis, Gin - Gingiva, Lar - Larynx, Lip - Lip, Max - Maxillary sinus, Nos - Nose, Ton - Tongue, Voc - Vocal cords
 - AT, - Malignant tumor, - Malignant tumor (stage I), - Malignant tumor (stage II), - Malignant tumor (stage III), - Malignant tumor (stage IV),
 - Malignant tumor (stage IVA), - NAT, - Normal tissue

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	58	M	Larynx	Squamous cell carcinoma	T4aN0M0	3	IVA	Malignant	
A2	2	58	M	Larynx	Squamous cell carcinoma	T4aN0M0	2	IVA	Malignant	
A3	3	56	M	Larynx	Squamous cell carcinoma	T4aN0M0	1	IVA	Malignant	
A4	4	56	M	Larynx	Squamous cell carcinoma	T4aN0M0	1	IVA	Malignant	
A5	5	36	M	Gingiva	Squamous cell carcinoma of left lower gum	T4N0M0	1	IV	Malignant	
A6	6	36	M	Gingiva	Squamous cell carcinoma of left lower gum	T4N0M0	1	IV	Malignant	
A7	7	79	M	Cheek	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
A8	8	79	M	Cheek	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
A9	9	75	M	Larynx	Squamous cell carcinoma	T2N0M0	1	II	Malignant	
A10	10	75	M	Larynx	Squamous cell carcinoma	T2N0M0	1	II	Malignant	
B1	11	63	F	Tongue	Squamous cell carcinoma	T1N0M0	1	I	Malignant	
B2	12	63	F	Tongue	Squamous cell carcinoma	T1N0M0	1	I	Malignant	
B3	13	78	M	Tongue	Squamous cell carcinoma	T2N0M0	1	II	Malignant	

B4	14	78	M	Tongue	Squamous cell carcinoma	T2N0M0	1	II	Malignant	
B5	15	81	M	Lip	Squamous cell carcinoma	T3N0M0	1	III	Malignant	
B6	16	81	M	Lip	Squamous cell carcinoma	T3N0M0	1	III	Malignant	
B7	17	64	M	Tongue	Squamous cell carcinoma	T2N0M0	1--2	II	Malignant	
B8	18	64	M	Tongue	Squamous cell carcinoma	T2N0M0	1--2	II	Malignant	
B9	19	50	M	Larynx	Squamous cell carcinoma	T4aN0M0	2	IVA	Malignant	
B10	20	50	M	Larynx	Squamous cell carcinoma	T4aN0M0	2	IVA	Malignant	
C1	21	60	M	Larynx	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
C2	22	60	M	Larynx	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
C3	23	55	M	Laryngopharynx	Squamous cell carcinoma	T2N0M0	1--2	II	Malignant	
C4	24	55	M	Laryngopharynx	Squamous cell carcinoma	T2N0M0	1--2	II	Malignant	
C5	25	57	F	Cheek	Squamous cell carcinoma of right cheek	T3N0M0	2	III	Malignant	
C6	26	57	F	Cheek	Squamous cell carcinoma of right cheek	T3N0M0	2	III	Malignant	
C7	27	58	M	Larynx	Squamous cell carcinoma	T2N2cM0	2	IVA	Malignant	
C8	28	58	M	Larynx	Squamous cell carcinoma	T2N2cM0	2	IVA	Malignant	
C9	29	53	M	Vocal cords	Squamous cell carcinoma of left vocal cords	T3N2bM0	2	IVA	Malignant	
C10	30	53	M	Vocal cords	Squamous cell carcinoma of left vocal cords	T3N2bM0	2	IVA	Malignant	
D1	31	60	M	Larynx	Squamous cell carcinoma	T3N0M0	3	III	Malignant	
D2	32	60	M	Larynx	Squamous cell carcinoma	T3N0M0	3	III	Malignant	
D3	33	78	M	Larynx	Squamous cell carcinoma	T4aN0M0	2	IVA	Malignant	
D4	34	78	M	Larynx	Squamous cell carcinoma	T4aN0M0	2	IVA	Malignant	
D5	35	59	M	Larynx	Squamous cell carcinoma	T4aN0M0	2	IVA	Malignant	
D6	36	59	M	Larynx	Squamous cell carcinoma	T4aN0M0	2	IVA	Malignant	
D7	37	60	M	Larynx	Squamous cell carcinoma	T3N0M0	2	III	Malignant	
D8	38	60	M	Larynx	Squamous cell carcinoma	T3N0M0	2	III	Malignant	
D9	39	63	F	Nose	Squamous cell carcinoma	T3N0M0	2	III	Malignant	
D10	40	63	F	Nose	Squamous cell carcinoma	T3N0M0	2	III	Malignant	
E1	41	49	M	Larynx	Squamous cell carcinoma	T4aN0M0	2	IVA	Malignant	
E2	42	49	M	Larynx	Squamous cell carcinoma	T4aN0M0	2	IVA	Malignant	
E3	43	47	F	Maxillary sinus	Squamous cell carcinoma	T1N0M0	2--3	I	Malignant	
E4	44	47	F	Maxillary sinus	Squamous cell carcinoma	T1N0M0	2--3	I	Malignant	
E5	45	40	M	Lip	Squamous cell carcinoma	T4aN1M0	2--3	IVA	Malignant	
E6	46	40	M	Larynx	Squamous cell carcinoma	T4aN1M0	2--3	IVA	Malignant	
E7	47	64	M	Larynx	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
E8	48	64	M	Larynx	Squamous cell carcinoma	T2N0M0	2	II	Malignant	
E9	49	57	M	Larynx	Squamous cell carcinoma	T4aN0M0	2--3	IVA	Malignant	
E10	50	57	M	Larynx	Squamous cell carcinoma	T4aN0M0	2--3	IVA	Malignant	
F1	51	46	M	Larynx	Squamous cell carcinoma	T3N0M0	2--3	III	Malignant	
F2	52	46	M	Larynx	Squamous cell carcinoma	T3N0M0	2--3	III	Malignant	
F3	53	63	M	Larynx	Squamous cell carcinoma	T3N0M0	3	III	Malignant	
F4	54	63	M	Larynx	Squamous cell carcinoma	T3N0M0	3	III	Malignant	
F5	55	60	M	Laryngopharynx	Squamous cell carcinoma	T2N0M0	3	II	Malignant	
F6	56	60	M	Laryngopharynx	Squamous cell carcinoma	T2N0M0	3	II	Malignant	
F7	57	43	M	Nose	Squamous cell carcinoma left nasal cavity	T2N0M0	3	III	Malignant	
F8	58	43	M	Nose	Squamous cell carcinoma left nasal cavity	T2N0M0	3	III	Malignant	
F9	59	56	M	Larynx	Squamous cell carcinoma	T4N1M0	3	IVA	Malignant	
F10	60	56	M	Larynx	Squamous cell carcinoma	T4N1M0	3	IVA	Malignant	
G1	61	28	M	Epiglottis	Epiglottis tissue	-	-	-	Normal	
G2	62	28	M	Epiglottis	Epiglottis tissue	-	-	-	Normal	
G3	63	59	M	Larynx	Adjacent normal larynx tissue	-	-	-	NAT	
G4	64	59	M	Larynx	Adjacent normal larynx tissue	-	-	-	NAT	
G5	65	66	M	Larynx	Adjacent normal larynx tissue	-	-	-	NAT	
G6	66	66	M	Larynx	Adjacent normal larynx tissue	-	-	-	NAT	
G7	67	45	M	Tongue	Tongue tissue	-	-	-	Normal	
G8	68	45	M	Tongue	Tongue tissue	-	-	-	Normal	
G9	69	48	M	Tongue	Tongue tissue	-	-	-	Normal	
G10	70	48	M	Tongue	Tongue tissue	-	-	-	Normal	
H1	71	50	M	Tongue	Tongue tissue	-	-	-	Normal	
H2	72	50	M	Tongue	Tongue tissue	-	-	-	Normal	
H3	73	35	M	Tongue	Tongue tissue	-	-	-	Normal	
H4	74	35	M	Tongue	Tongue tissue	-	-	-	Normal	

H5	75	18	F	Tongue	Tongue tissue	-	-	-	Normal	
H6	76	18	F	Tongue	Tongue tissue	-	-	-	Normal	
H7	77	19	F	Tongue	Tongue tissue	-	-	-	Normal	
H8	78	19	F	Tongue	Tongue tissue	-	-	-	Normal	
H9	79	58	M	Nose	Cancer adjacent nose tissue	-	-	-	AT	
H10	80	58	M	Nose	Cancer adjacent nose tissue	-	-	-	AT	
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)		-		Malignant	

AMSBIO | www.amsbio.com | info@amsbio.com

AMSBIO LLC

USA & Canada



1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

AMSBIO Europe BV

EU



Berenkoog 41,
1822 BH Alkmaar,
Netherlands
T: +31 (0) 72 8080244
F: +31 (0) 72 8080142

AMS Biotechnology (Europe) Ltd

UK & Rest of the World



184 Park Drive, Milton Park
Abingdon OX14 4SE
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

AMS Biotechnology (Europe) Ltd

Switzerland



Via Lisano 3,
(CP.683)
CH-6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85

AMSBIO Europe BV

Deutschland



T: +49 (0) 69 779099
F: +49 (0) 69 13376880